Suppr超能文献

在针对人类多能干细胞来源心肌细胞功能进行优化的条件下,揭示了由MYBPC3突变引起的收缩缺陷。

Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function.

作者信息

Birket Matthew J, Ribeiro Marcelo C, Kosmidis Georgios, Ward Dorien, Leitoguinho Ana Rita, van de Pol Vera, Dambrot Cheryl, Devalla Harsha D, Davis Richard P, Mastroberardino Pier G, Atsma Douwe E, Passier Robert, Mummery Christine L

机构信息

Department of Anatomy and Embryology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands.

Department of Anatomy and Embryology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands; Department of Cardiology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands.

出版信息

Cell Rep. 2015 Oct 27;13(4):733-745. doi: 10.1016/j.celrep.2015.09.025. Epub 2015 Oct 17.

Abstract

Maximizing baseline function of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) is essential for their effective application in models of cardiac toxicity and disease. Here, we aimed to identify factors that would promote an adequate level of function to permit robust single-cell contractility measurements in a human induced pluripotent stem cell (hiPSC) model of hypertrophic cardiomyopathy (HCM). A simple screen revealed the collaborative effects of thyroid hormone, IGF-1 and the glucocorticoid analog dexamethasone on the electrophysiology, bioenergetics, and contractile force generation of hPSC-CMs. In this optimized condition, hiPSC-CMs with mutations in MYBPC3, a gene encoding myosin-binding protein C, which, when mutated, causes HCM, showed significantly lower contractile force generation than controls. This was recapitulated by direct knockdown of MYBPC3 in control hPSC-CMs, supporting a mechanism of haploinsufficiency. Modeling this disease in vitro using human cells is an important step toward identifying therapeutic interventions for HCM.

摘要

最大化人多能干细胞衍生心肌细胞(hPSC-CMs)的基线功能对于其在心脏毒性和疾病模型中的有效应用至关重要。在此,我们旨在确定能够促进功能达到适当水平的因素,以便在肥厚型心肌病(HCM)的人诱导多能干细胞(hiPSC)模型中进行可靠的单细胞收缩性测量。一项简单的筛选揭示了甲状腺激素、胰岛素样生长因子-1(IGF-1)和糖皮质激素类似物地塞米松对hPSC-CMs的电生理学、生物能量学和收缩力产生的协同作用。在这种优化条件下,编码肌球蛋白结合蛋白C的基因MYBPC3发生突变(该基因突变会导致HCM)的hiPSC-CMs,其收缩力产生明显低于对照组。通过在对照hPSC-CMs中直接敲低MYBPC3可重现这一现象,支持单倍剂量不足机制。利用人类细胞在体外对这种疾病进行建模是朝着确定HCM治疗干预措施迈出的重要一步。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a32/4644234/6bfc4c730103/fx1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验